Investor Relations
-
Message from the Chairman and CEO
We are working to meet the expectations of our shareholders and investors by enhancing corporate value.
-
Business Results For the First Nine Months of the Fiscal Year Ending March 31, 2020
IR Information
-
-
Advanced Medical Care Approval for Cancer Gene Panel Testing at the Time of Initial Treatment
- Prospective Study to Assess the Feasibility and Clinical Utility of Comprehensive Genomic Profiling at the Time of Initial Treatment of Patients with Solid Tumors - (PDF：122KB) -
-
Sysmex Obtains First Marketing Approval in Japan for the Novel Coronavirus Nucleic Acid Detection Kits (RT-PCR Method)
- Aiming for early introduction of test kits for in vitro diagnostic medical devices in medical institutions - (PDF：183KB) -
- Announcement of Organizational and Personnel Changes (PDF：376KB)
-
- Sysmex to Introduce New Globally Consistent Job-Based HR Management System with the Aim of Realizing Sustainable Growth
-
- Posted the 17th Technology Presentation
